RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Short Interest Update

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) saw a significant decrease in short interest in July. As of July 15th, there was short interest totaling 201 shares, a decrease of 40.5% from the June 30th total of 338 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 338 shares, the short-interest ratio is presently 0.6 days.

RCN Pareto Strategic Allocation ETF Stock Performance

Shares of PRTO traded up $0.43 during trading hours on Thursday, reaching $27.19. The stock had a trading volume of 106 shares. RCN Pareto Strategic Allocation ETF has a 12 month low of $24.68 and a 12 month high of $28.16. The stock has a market capitalization of $603.05 million, a price-to-earnings ratio of -28.32 and a beta of 0.60.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.